NAUT
What one share of Nautilus Biotechnology holds
Laboratory Analytical Instruments
On June 9, 2021 (the “Closing Date”), Nautilus Biotechnology, Inc., a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp III (“ARYA”)), consummated the business combination (the “Business Combination”) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the “Business Combination Agreement”), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (“Mako Merger Sub”), and…
Nautilus Biotechnology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.45 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.41 |
| Cash and investments | $0.10 |
| Book value | $1.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$0.54 | $0.03 | −$0.51 | — | −$0.90 |
| 2021 | — | −$0.60 | $0.03 | −$0.49 | — | $2.92 |
| 2022 | — | −$0.46 | $0.02 | −$0.39 | — | $2.52 |
| 2023 | — | −$0.51 | $0.02 | −$0.43 | — | $2.12 |
| 2024 | — | −$0.56 | $0.02 | −$0.49 | — | $1.66 |
| 2025 | — | −$0.47 | $0.01 | −$0.41 | — | $1.24 |